RxDoctor Payments Data

Bassam Yousef, MD

Hospitalist · Evansville, INNPI 1598745184

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Johnson & Johnson at 26.6% of the total.

$791in general payments, 2019–2025

Across 40 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$210
  • Novartis$173
  • Inari Medical, Inc.$105
  • Merck$89
  • Pfizer$56
  • Viatris Specialty LLC$49
  • plus $108 from 4 others

What the payments were for

  • Food & beverage$791100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$791 in reported general payments places this provider in the 85th percentile of 423 hospitalist providers in Indiana.

See all hospitalist providers in Indiana

Medicare billing

Part B allowed, 2024
$102,279
Medicare patients
287
Services billed
975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban36$21,430
Midodrine Hcl18$1,619
CefuroximeCefuroxime Axetil23$331
Pantoprazole Sodium23$188
Metoprolol Succinate23$174
Atorvastatin Calcium44$166
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav15$160
Digoxin12$160
Hydralazine Hcl21$151
Furosemide30$112
Spironolactone17$106
Amlodipine Besylate26$75
Carvedilol18$61
ClopidogrelClopidogrel Bisulfate14$60
Prednisone27$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$56$21,43036 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 423 hospitalist providers in Indiana.

Other hospitalist in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →